Akebia Therapeutics (AKBA) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vogenx is the larger company by market cap ($259.8 million vs $225.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | VOGX |
|---|---|---|
| Share price | $0.8148 | $17.49 |
| Market cap | $225.79M | $259.82M |
| 1-day change | -6.71% | +8.23% |
| YTD return | -45.75% | — |
| 1-year return | -70.39% | — |
| 5-year return | -69.35% | — |
| EPS (TTM) | $-0.12 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $38.41 |
| 52-week low | $0.814 | $12.95 |
| Distance from 52-week high | -74.54% | -54.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +381.10% | +214.47% |
| Average volume | 6.13M | 188.79K |
| Shares outstanding | 277.11M | 14.86M |
| Employees | 194 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
AKBA vs VOGX FAQ
Which is bigger, Akebia Therapeutics or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $259.82M compared with $225.79M for Akebia Therapeutics (AKBA).
Are Akebia Therapeutics and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.